KEGG DRUG: Ozoralizumab

DRUG: Ozoralizumab

Entry

D09944                      Drug

Name

Ozoralizumab (USAN);
Ozoralizumab (genetical recombination) (JAN);
Nanozora (TN)

Formula

C1682H2608N472O538S12

Exact mass

38410.7875

Mol weight

38434.35

Class

Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor

Remark

Therapeutic category:

3999

Product:

D09944<JP>

Efficacy

Anti-inflammatory, Anti-TNF-alpha antibody

Type

Monoclonal antibody, nanobody

Comment

Treatment of inflammation

Target

TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]

Pathway

hsa04010

MAPK signaling pathway

hsa04060

Cytokine-cytokine receptor interaction

hsa04350

TGF-beta signaling pathway

Interaction

Brite

Therapeutic category of drugs in Japan [BR:br08301]
3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D09944  Ozoralizumab (USAN); Ozoralizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   DG01936  TNF inhibitor
    D09944  Ozoralizumab
Drug classes [BR:br08332]
Immunological agent
  DG01936  TNF inhibitor
   D09944  Ozoralizumab
Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D09944  Ozoralizumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D09944  Ozoralizumab (USAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D09944
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D09944

Other DBs

CAS:	1167985-17-2

PubChem:

124490626

LinkDB

» Japanese version » Back

DBGET integrated database retrieval system